{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T21:14:43Z","timestamp":1789852483445,"version":"4.0.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2010,2,24]],"date-time":"2010-02-24T00:00:00Z","timestamp":1266969600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["World J Urol"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1007\/s00345-010-0519-5","type":"journal-article","created":{"date-parts":[[2010,2,23]],"date-time":"2010-02-23T15:53:07Z","timestamp":1266940387000},"page":"303-309","source":"Crossref","is-referenced-by-count":33,"title":["Update on systemic therapies of metastatic renal cell carcinoma"],"prefix":"10.1007","volume":"28","author":[{"given":"E.","family":"Herrmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Bierer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"W\u00fclfing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,2,24]]},"reference":[{"key":"519_CR1","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3322\/CA.2007.0010","volume":"58","author":"A Jemal","year":"2008","unstructured":"Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ (2008) Cancer statistics, 2008. CA Cancer J Clin 58:71\u201396","journal-title":"CA Cancer J Clin"},{"key":"519_CR2","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s00432-008-0515-y","volume":"135","author":"AJ Schrader","year":"2009","unstructured":"Schrader AJ, Rauer-Bruening S, Olbert PJ, Hegele A, Rustemeier J, Timmesfeld N, Varga Z, Hofmann R (2009) Incidence and long-term prognosis of papillary renal cell carcinoma. J Cancer Res Clin Oncol 135:799\u2013805","journal-title":"J Cancer Res Clin Oncol"},{"key":"519_CR3","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1200\/JCO.2005.07.055","volume":"23","author":"JJ Patard","year":"2005","unstructured":"Patard JJ, Leray E, Rioux-Leclercq N, Cindolo L, Ficarra V, Zisman A, De La Taille A, Tostain J, Artibani W, Abbou CC, Lobel B, Guille F, Chopin DK, Mulders PF, Wood CG, Swanson DA, Figlin RA, Belldegrun AS, Pantuck AJ (2005) Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol 23:2763\u20132771","journal-title":"J Clin Oncol"},{"key":"519_CR4","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1097\/00000478-200305000-00005","volume":"27","author":"JC Cheville","year":"2003","unstructured":"Cheville JC, Lohse CM, Zincke H, Weaver AL, Blute ML (2003) Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol 27:612\u2013624","journal-title":"Am J Surg Pathol"},{"key":"519_CR5","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMoa003013","volume":"345","author":"RC Flanigan","year":"2001","unstructured":"Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, Caton JR Jr, Munshi N, Crawford ED (2001) Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 345:1655\u20131659","journal-title":"N Engl J Med"},{"key":"519_CR6","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/S0140-6736(01)06103-7","volume":"358","author":"GH Mickisch","year":"2001","unstructured":"Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R (2001) Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 358:966\u2013970","journal-title":"Lancet"},{"key":"519_CR7","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0302-2838(03)00191-X","volume":"44","author":"I Bleumer","year":"2003","unstructured":"Bleumer I, Oosterwijk E, De Mulder P, Mulders PF (2003) Immunotherapy for renal cell carcinoma. Eur Urol 44:65\u201375","journal-title":"Eur Urol"},{"key":"519_CR8","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","volume":"356","author":"B Escudier","year":"2007","unstructured":"Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125\u2013134","journal-title":"N Engl J Med"},{"key":"519_CR9","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/S0140-6736(07)61904-7","volume":"370","author":"B Escudier","year":"2007","unstructured":"Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Melichar B, Bajetta E, Gorbunova V, Bay JO, Bodrogi I, Jagiello-Gruszfeld A, Moore N (2007) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370:2103\u20132111","journal-title":"Lancet"},{"key":"519_CR10","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","volume":"356","author":"RJ Motzer","year":"2007","unstructured":"Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Eng K Med 356:115\u2013124","journal-title":"N Eng K Med"},{"key":"519_CR11","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","volume":"356","author":"G Hudes","year":"2007","unstructured":"Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O\u2019Toole T, Lustgarten S, Moore L, Motzer RJ (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356:2271\u20132281","journal-title":"N Engl J Med"},{"key":"519_CR12","unstructured":"Kay A, Motzer RJ, Figlin R, Escudier B, Oudard S, Porta C, Hutson T, Bracarda S, Hollaender N, Urbanowitz G, Ravaud A (2009) Updated data from a phase III randomized trial of everolimus (RAD001) versus PBO in metastatic renal cell carcinoma (mRCC). J Clin Oncol (Genitourinary ASCO Suppl) Abstract No 278"},{"key":"519_CR13","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s00345-008-0237-4","volume":"26","author":"JJ Patard","year":"2008","unstructured":"Patard JJ, Pouessel D, Bensalah K, Culine S (2008) Targeted therapy in renal cell carcinoma. World J Urol 26:135\u2013140","journal-title":"World J Urol"},{"key":"519_CR14","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1200\/JCO.2005.02.2194","volume":"24","author":"S Faivre","year":"2006","unstructured":"Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, Bello C, Deprimo S, Brega N, Massimini G, Armand JP, Scigalla P, Raymond E (2006) Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24:25\u201335","journal-title":"J Clin Oncol"},{"key":"519_CR15","first-page":"5465","volume":"9","author":"AM O\u2019Farrell","year":"2003","unstructured":"O\u2019Farrell AM, Foran JM, Fiedler W, Serve H, Paquette RL, Cooper MA, Yuen HA, Louie SG, Kim H, Nicholas S, Heinrich MC, Berdel WE, Bello C, Jacobs M, Scigalla P, Manning WC, Kelsey S, Cherrington JM (2003) An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin Cancer Res 9:5465\u20135476","journal-title":"Clin Cancer Res"},{"key":"519_CR16","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1200\/JCO.2002.20.1.289","volume":"20","author":"RJ Motzer","year":"2002","unstructured":"Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M (2002) Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20:289\u2013296","journal-title":"J Clin Oncol"},{"key":"519_CR17","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa021491","volume":"349","author":"JC Yang","year":"2003","unstructured":"Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349:427\u2013434","journal-title":"N Engl J Med"},{"key":"519_CR18","doi-asserted-by":"crossref","unstructured":"Escudier B, Bellmunt J, Negrier S, Melichar B, Bracarda S, Ravaud A, Golding S, Jethwa S (2009) Final results of the phase III randomized, double-blind AVOREN trial of first-line bevacizumab (BEV)\u00a0+\u00a0interferon-\u03b12a (IFN) in metastatic renal cell carcinoma (mRCC). J Clin Oncol (Suppl) 27:15\u00a0s (Abstract 5020)","DOI":"10.1200\/jco.2009.27.15_suppl.5020"},{"key":"519_CR19","doi-asserted-by":"crossref","unstructured":"Rini BI, Halabi S, Rosenberg J, Stadler WM, Vaena DA, Atkins JN, Picus J, Czaykowski P, Dutcher J, Small EJ (2009) Bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in patients with metastatic renal cell carcinoma: Results of overall survival for CALGB 90206. J Clin Oncol (Suppl) 27:18\u00a0s (Abstract LBA5019)","DOI":"10.1200\/jco.2009.27.18s.lba5019"},{"key":"519_CR20","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1200\/JCO.2004.08.185","volume":"22","author":"MB Atkins","year":"2004","unstructured":"Atkins MB, Hidalgo M, Stadler WM, Logan TF, Dutcher JP, Hudes GR, Park Y, Liou SH, Marshall B, Boni JP, Dukart G, Sherman ML (2004) Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22:909\u2013918","journal-title":"J Clin Oncol"},{"key":"519_CR21","doi-asserted-by":"crossref","unstructured":"Dutcher JP, Szczylik C, Tannir N, Benedetto P, Ruff P, Hsu A, Berkenblit A Thiele A, Strahs A, Feingold J (2007) Correlation of survival with tumor histology, age, and prognostic risk group for previously untreated patients with advanced renal cell carcinoma (adv RCC) receiving temsirolimus (TEMSR) or interferon-alpha (IFN). J Clin Oncol (Suppl) 25:243\u00a0s (Abstract 5033)","DOI":"10.1200\/jco.2007.25.18_suppl.5033"},{"key":"519_CR22","doi-asserted-by":"crossref","unstructured":"Hutson TE, Davis ID, Machiels JP, de Souza PL, Hong BF, Rottey S, Baker KL, Crofts T, Pandite L, Figlin (2007) Pazopanib (GW786034) is active in metastatic renal cell carcinoma (RCC): Interim results of a phase II randomized discontinuation trial (RDT). J Clin Oncol (Suppl) 25:18\u00a0s (Abstract 5031)","DOI":"10.1200\/jco.2007.25.18_suppl.5031"},{"key":"519_CR23","doi-asserted-by":"crossref","unstructured":"Sternberg CS, Szczylik C, Lee E, Salman PV, Mardiak J, Davis ID, Pandite L, Chen M, McCann L, Hawkins R (2009) A randomized, double-blind phase III study of pazopanib in treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma (RCC). J Clin Oncol (Suppl) 27:15\u00a0s (Abstract 5021)","DOI":"10.1200\/jco.2009.27.15_suppl.5021"},{"key":"519_CR24","first-page":"2957","volume":"62","author":"KJ Turner","year":"2002","unstructured":"Turner KJ, Moore JW, Jones A, Taylor CF, Cuthbert-Heavens D, Han C, Leek RD, Gatter KC, Maxwell PH, Ratcliffe PJ, Cranston D, Harris AL (2002) Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation. Cancer 62:2957\u20132961","journal-title":"Cancer"},{"key":"519_CR25","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1200\/JCO.2005.06.124","volume":"23","author":"D Strumberg","year":"2005","unstructured":"Strumberg D, Richly H, Hilger RA, Schleucher N, Korfee S, Tewes M, Faghih M, Brendel E, Voliotis D, Haase CG, Schwartz B, Awada A, Voigtmann R, Scheulen ME, Seeber S (2005) Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 23:965\u2013972","journal-title":"J Clin Oncol"},{"key":"519_CR26","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2008.19.5511","volume":"27","author":"B Escudier","year":"2009","unstructured":"Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Staehler M, Negrier S, Chevreau C, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Anderson S, Hofilena G, Shan M, Pena C, Lathia C, Bukowski RM (2009) Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 27:3312\u20133318","journal-title":"J Clin Oncol"},{"key":"519_CR27","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1016\/j.juro.2007.07.030","volume":"178","author":"RJ Motzer","year":"2007","unstructured":"Motzer RJ, Michaelson MD, Rosenberg J, Bukowski RM, Curti BD, George DJ, Hudes GR, Redman BG, Margolin KA, Wilding G (2007) Sunitinib efficacy against advanced renal cell carcinoma. J Urol 178:1883\u20131887","journal-title":"J Urol"},{"key":"519_CR28","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1001\/jama.295.21.2516","volume":"295","author":"RJ Motzer","year":"2006","unstructured":"Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, Redman BG, Margolin KA, Merchan JR, Wilding G, Ginsberg MS, Bacik J, Kim ST, Baum CM, Michaelson MD (2006) Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295:2516\u20132524","journal-title":"JAMA"},{"key":"519_CR29","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1159\/000151369","volume":"74","author":"E Herrmann","year":"2008","unstructured":"Herrmann E, Bierer S, Gerss J, Kopke T, Hertle L, Wulfing C (2008) Prospective comparison of sorafenib and sunitinib for second-line treatment of cytokine-refractory kidney cancer patients. Oncology 74:216\u2013222","journal-title":"Oncology"},{"key":"519_CR30","doi-asserted-by":"crossref","unstructured":"Jac J, Giessinger S, Khan M, Willis J, Chiang S, Amato R (2007) A phase II trial of RAD001 in patients (Pts) with metastatic renal cell carcinoma (MRCC). J Clin Oncol (Suppl) 25:18\u00a0s (Abstract 5107)","DOI":"10.1200\/jco.2007.25.18_suppl.5107"},{"key":"519_CR31","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/j.eururo.2008.08.066","volume":"54","author":"S Bracarda","year":"2008","unstructured":"Bracarda S, De Simone V (2008) Sequential therapies in metastatic renal cell carcinoma: option or strategy? Eur Urol 54:1219\u20131220","journal-title":"Eur Urol"},{"key":"519_CR32","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1007\/s00345-004-0470-4","volume":"23","author":"K Rohrmann","year":"2005","unstructured":"Rohrmann K, Staehler M, Haseke N, Bachmann A, Stief CG, Siebels M (2005) Immunotherapy in metastatic renal cell carcinoma. World J Urol 23:196\u2013201","journal-title":"World J Urol"},{"key":"519_CR33","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s00345-004-0479-8","volume":"23","author":"OA Brinkmann","year":"2005","unstructured":"Brinkmann OA, Bruns F, Gosheger G, Micke O, Hertle L (2005) Treatment of bone metastases and local recurrence from renal cell carcinoma with immunochemotherapy and radiation. World J Urol 23:185\u2013190","journal-title":"World J Urol"},{"key":"519_CR34","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/cncr.23552","volume":"113","author":"JA Klapper","year":"2008","unstructured":"Klapper JA, Downey SG, Smith FO, Yang JC, Hughes MS, Kammula US, Sherry RM, Royal RE, Steinberg SM, Rosenberg S (2008) High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma: a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006. Cancer 113:293\u2013301","journal-title":"Cancer"},{"key":"519_CR35","doi-asserted-by":"crossref","first-page":"3714","DOI":"10.1158\/1078-0432.CCR-04-2019","volume":"11","author":"M Atkins","year":"2005","unstructured":"Atkins M, Regan M, McDermott D, Mier J, Stanbridge E, Youmans A, Febbo P, Upton M, Lechpammer M, Signoretti S (2005) Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res 11:3714\u20133721","journal-title":"Clin Cancer Res"},{"key":"519_CR36","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.eururo.2009.01.003","volume":"55","author":"C Eichelberg","year":"2009","unstructured":"Eichelberg C, Junker K, Ljungberg B, Moch H (2009) Diagnostic and prognostic molecular markers for renal cell carcinoma: a critical appraisal of the current state of research and clinical applicability. Eur Urol 55:851\u2013863","journal-title":"Eur Urol"},{"key":"519_CR37","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/sj.bjc.6605167","volume":"101","author":"JS Thompson Coon","year":"2009","unstructured":"Thompson Coon JS, Liu Z, Hoyle M, Rogers G, Green C, Moxham T, Welch K, Stein K (2009) Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness. Br J Cancer 101:238\u2013243","journal-title":"Br J Cancer"},{"key":"519_CR38","doi-asserted-by":"crossref","unstructured":"Sablin MP, Bouaita L, Balleyguier C, Gautier J, Celier C, Balcaceres JL, Oudard S, Ravaud A, N\u00e9grier S, Escudier B (2007) Sequential use of sorafenib and sunitinib in renal cancer: Retrospective analysis in 90 patients. J Clin Oncol (Suppl) 25:18\u00a0s (Abstract 5038)","DOI":"10.1200\/jco.2007.25.18_suppl.5038"},{"key":"519_CR39","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/cncr.24009","volume":"115","author":"AZ Dudek","year":"2009","unstructured":"Dudek AZ, Zolnierek J, Dham A, Lindgren BR, Szczylik C (2009) Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. Cancer 115:61\u201367","journal-title":"Cancer"},{"key":"519_CR40","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.eururo.2008.07.051","volume":"54","author":"C Eichelberg","year":"2008","unstructured":"Eichelberg C, Heuer R, Chun FK, Hinrichs K, Zacharias M, Huland H, Heinzer H (2008) Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis. Eur Urol 54:1373\u20131378","journal-title":"Eur Urol"},{"key":"519_CR41","doi-asserted-by":"crossref","first-page":"4469","DOI":"10.1200\/JCO.2009.22.6480","volume":"27","author":"G Di Lorenzo","year":"2009","unstructured":"Di Lorenzo G, Carteni G, Autorino R, Bruni G, Tudini M, Rizzo M, Aieta M, Gonnella A, Rescigno P, Perdona S, Giannarini G, Pignata S, Longo N, Palmieri G, Imbimbo C, De Laurentiis M, Mirone V, Ficorella C, De Placido S (2009) Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer. J Clin Oncol 27:4469\u20134474","journal-title":"J Clin Oncol"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-010-0519-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00345-010-0519-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-010-0519-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,24]],"date-time":"2021-10-24T00:15:04Z","timestamp":1635034504000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00345-010-0519-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2,24]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["519"],"URL":"https:\/\/doi.org\/10.1007\/s00345-010-0519-5","relation":{},"ISSN":["0724-4983","1433-8726"],"issn-type":[{"value":"0724-4983","type":"print"},{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,2,24]]}}}